Analyst Price Target is $42.33
▲ +726.82% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Orchard Therapeutics in the last 3 months. The average price target is $42.33, with a high forecast of $50.00 and a low forecast of $37.00. The average price target represents a 726.82% upside from the last price of $5.12.
Current Consensus is
Hold
The current consensus among 3 investment analysts is to hold stock in Orchard Therapeutics. This rating has held steady since January 2023, when it changed from a Buy consensus rating.
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.
Read More